190 related articles for article (PubMed ID: 33378962)
1. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
[TBL] [Abstract][Full Text] [Related]
2. Anti-oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient-derived tumor xenograft model.
Yang CY; Lin CK; Hsieh CC; Tsao CH; Lin CS; Peng B; Chen YT; Ting CC; Chang WC; Lin GJ; Sytwu HK; Chen YW
Head Neck; 2019 May; 41(5):1260-1269. PubMed ID: 30537218
[TBL] [Abstract][Full Text] [Related]
3. Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines.
Zhang L; Yu JS
J Neurooncol; 2019 Jul; 143(3):429-436. PubMed ID: 31152305
[TBL] [Abstract][Full Text] [Related]
4. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.
Wu T; Tang C; Tao R; Yong X; Jiang Q; Feng C
Front Immunol; 2021; 12():693881. PubMed ID: 34552581
[TBL] [Abstract][Full Text] [Related]
5. The Immunomodulatory Effect of Triptolide on Mesenchymal Stromal Cells.
He H; Takahashi A; Mukai T; Hori A; Narita M; Tojo A; Yang T; Nagamura-Inoue T
Front Immunol; 2021; 12():686356. PubMed ID: 34484183
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells.
Wudtiwai B; Makeudom A; Krisanaprakornkit S; Pothacharoen P; Kongtawelert P
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500779
[TBL] [Abstract][Full Text] [Related]
7. Triptolide exerts anti-tumor effect on oral cancer and KB cells in vitro and in vivo.
Chen YW; Lin GJ; Chia WT; Lin CK; Chuang YP; Sytwu HK
Oral Oncol; 2009 Jul; 45(7):562-8. PubMed ID: 19359213
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
Gao A; Pan X; Yang X; Lin Z
Invest New Drugs; 2021 Aug; 39(4):1132-1138. PubMed ID: 33594603
[TBL] [Abstract][Full Text] [Related]
9. Triptolide represses oral cancer cell proliferation, invasion, migration, and angiogenesis in co-inoculation with U937 cells.
Yang CY; Lin CK; Lin GJ; Hsieh CC; Huang SH; Ma KH; Shieh YS; Sytwu HK; Chen YW
Clin Oral Investig; 2017 Jan; 21(1):419-427. PubMed ID: 27073100
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
[TBL] [Abstract][Full Text] [Related]
12. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
[TBL] [Abstract][Full Text] [Related]
13. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
Wu Q; Zhao Y; Sun Y; Yan X; Wang P
Oncol Rep; 2018 Mar; 39(3):1461-1468. PubMed ID: 29328389
[TBL] [Abstract][Full Text] [Related]
14. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
[TBL] [Abstract][Full Text] [Related]
15. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
[TBL] [Abstract][Full Text] [Related]
16. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
17. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y
Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463
[TBL] [Abstract][Full Text] [Related]
19. Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells.
Liang M; Fu J
Cancer Lett; 2008 Nov; 270(2):337-41. PubMed ID: 18572307
[TBL] [Abstract][Full Text] [Related]
20. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
PeerJ; 2023; 11():e15922. PubMed ID: 37663280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]